论文部分内容阅读
2012年2月,美国FDA批准了Bayer医疗保健制药有限公司开发的由屈螺酮(drospirenone)0.25 mg和雌二醇(estradiol)0.5 mg组成的复合片剂Angeliq,用于一日1次口服治疗具有完整子宫妇女与绝经相关的中至重度血管舒缩症状。
In February 2012, the US FDA approved Angeliq, a combination tablet of drospirenone 0.25 mg and estradiol 0.5 mg developed by Bayer Healthcare Pharmaceuticals for oral once-a-day treatment Moderate to severe vasomotor symptoms associated with menopause in women with intact uterus.